B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Director – Global Digital & Technology Systems

Full-TimeUpdated on 10/21/2026
$172.5k - $232.5k/yr+ Annual bonus eligibility + Discretionary equity awards + Employee Stock Purchase Plan
Expert
Bachelor's
Remote in USA
RemoteRemote within the US; travel required less than 15%.
IT OperationsEnterprise Applications

About the job

Requirements
  • At least 10 years of experience working on validated applications in a pharmaceutical or regulated environment, primarily clinical applications and/or systems management in the pharmaceutical or medical device industry, especially in CTMS, eTMF, IRT, EDC, and SSU management.
  • At least 8 years of experience working in a GxP or regulated environment with a strong understanding of SLC methodology, 21 CFR Part 11, and GAMP principles.
  • At least 5 years of proven senior-level leadership managing a team of direct reports and associate staff.
  • Proven experience overseeing the direction, planning, installation, implementation, and maintenance of software solutions, especially in SaaS or hybrid-cloud environments.
  • Good working knowledge of O365, Active Directory technology and schema, and SaaS-to-SaaS application integration frameworks.
  • Extensive experience in business and technical analysis, including developing requirements and translating them into data-driven and technical solutions.
  • Strong expertise in data management practices, including data integrity, accuracy, and reliability.
  • Significant experience delivering technical projects and managing multiple initiatives across diverse functions in a global environment.
  • Ability to quickly learn and adapt to several technology areas, with a proactive approach to industry trends and innovations.
  • Strong process-improvement skills and orientation.
  • Ability to communicate ideas in technical and user-friendly language.
  • Proven business and technology skills, with success providing customer-oriented technology solutions.
  • Bachelor's degree in Computer Science or Information Technology.
  • Ability to manage employees and contingent workers at global sites, including coaching and mentoring staff and providing training and professional development.
  • Effective leadership and communication skills, and ability to develop people while working across broad direct and matrixed relationships.
  • Understanding of pharmaceutical research and development, particularly the Clinical Operations function.
  • Comprehensive understanding of how AI solutions integrate within external systems and platforms, including machine-learning lifecycles, foundational models, and requirements for AI-ready data.
  • Ability to articulate the business value of external systems and platforms to clinical leadership and explain their strategic roadmap alignment with organizational goals.
Responsibilities
  • Own end-to-end lifecycle management for the portfolio of external systems and solutions used by Global Clinical Operations (GCO).
  • Oversee end-to-end management of GCO external systems.
  • Implement and deliver systems, applications, and projects that meet GCO business needs, including initiatives supporting GCO goals and objectives.
  • Provide data, digital, and technology systems expertise to GCO stakeholders for their domain-related needs.
  • Coordinate and drive system maintenance, including security patching, version upgrades, enhancements, and configuration changes to improve business processes, address gaps, enable automation, and support organizational growth.
  • Collaborate with GCO and GRDTS leadership to develop long-term strategies for external-system enhancements and technology investments.
  • Partner with stakeholders and subject matter experts to develop business cases that justify and prioritize system initiatives in alignment with the overall business plan.
  • Develop and manage budgets for external systems in alignment with organizational objectives and cost efficiency.
  • Ensure data integrity, security, and appropriate governance of information processed through external systems.
  • Coordinate and manage incident response for external-system issues, ensuring timely resolution and stakeholder communication.
  • Create and maintain documentation covering system architecture, functionality, and operational procedures.
  • Provide end-user guidance and support, and facilitate training to improve system utilization and productivity.
  • Identify risks associated with GCO external systems, establish mitigation strategies, and ensure regulatory compliance.
  • Engage and collaborate with third-party vendors, service providers, and stakeholders to manage contracts, performance, and service-level agreements.
  • Foster cross-functional collaboration to integrate clinical systems with corporate enterprise systems.
  • Collaborate with GRDTS capabilities and teams, including Technology & Systems Engineering and GRDTS Operations, to deliver solutions for GCO within allocated budgets.
  • Ensure GCO systems and data platforms comply with pharmaceutical industry regulations, internal functional and enterprise policies, and security policies.
  • Liaise with computer-system vendors, IT partners, audit, and compliance teams to coordinate system implementation and change activities.
  • Work within an operating model supporting current and future GCO technology needs, including requirements management, solutioning, build, implementation, and administration of global Development platforms, master data, and system interfaces.
  • Lead, mentor, and manage the GCO Systems Management team responsible for end-to-end lifecycle management of external GCO systems and platforms.
  • Foster a culture of innovation and accountability and drive professional development.
  • Ensure systems and platforms comply with pharmaceutical regulations and internal security policies.
  • Ensure the team is trained in and embeds CSV, compliance, and health-authority requirements into operational activities.
  • Collaborate with R&D functions and teams on standards and best practices to achieve business goals.
  • Engage with peers to define, sponsor, and execute continuous improvements.
  • Translate long-term clinical objectives into a multi-year system capability roadmap for external GCO systems.
  • Translate clinical workflows into structural, technical system, and data requirements.
  • Align clinical functions, internal IT groups, and external vendors around external-systems standards.
  • Oversee end-to-end delivery of digital and technology solutions, from initial scoping and vendor selection through deployment and value realization.
  • Develop the GCO data, digital, and technology roadmap for external systems, mapping technology solutions to clinical capability milestones.
  • Create business-capability maps of current and future technical capabilities across GCO and their relationships to other functions.
  • Produce detailed, prioritized product-requirements backlogs for the Systems Engineering team to integrate or enhance platforms.
  • Create conceptual design and specification documents for existing GCO platforms and systems and their interactions with other systems.
  • Prepare vendor-selection and proof-of-concept briefs, including formal evaluations, technical scores, and business cases for onboarding vendor platforms or specialized scientific AI tools.
  • Co-author platform operating models and governance structures with Systems Engineering and GTS to keep GCO platforms stable, highly available, and optimized in production.
  • Deliver and launch AOP projects based on approved requirements, specifications, development activities, and implementation plans.
Desired Qualifications
  • Working knowledge of IaaS, including Amazon Web Services and Azure, and PaaS and SaaS architectures and technology options.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • Wellness Program
  • Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.